Stereotaxis Reports 19% Revenue Decline and $6.5 Million Net Loss in Q3 2025

Stereotaxis, Inc. reported a decline in revenue for the third quarter of 2025, with total revenue reaching $7.5 million, down 19% from $9.2 million in the same period last year. The decrease was primarily attributed to a significant drop in system sales, which fell to $1.9 million from $4.4 million. However, revenue from disposable interventional devices, services, and accessories increased by approximately 17%, totaling $5.6 million, driven by the full quarter impact of post-acquisition sales from Access Point Technologies EP, Inc. (APT) and new magnetic disposable device sales.

In terms of profitability, Stereotaxis reported a net loss of $6.5 million for the third quarter, slightly higher than the $6.2 million loss recorded in the same quarter of 2024. The company’s gross margin improved to 55% from 45% year-over-year, largely due to a favorable change in product mix. Operating expenses remained relatively stable, with research and development costs at $2.5 million and sales and marketing expenses decreasing to $2.9 million, reflecting lower headcount and third-party commissions.

Stereotaxis has made significant strategic moves, including the acquisition of APT, which was completed on July 31, 2024. This acquisition is expected to enhance the company’s capabilities in developing a range of interventional devices. The integration of APT has already contributed to increased sales of non-magnetic disposable devices. Additionally, Stereotaxis has received regulatory approvals for its GenesisX RMN System and the MAGiC catheter, which are anticipated to bolster its market presence.

Operationally, Stereotaxis reported a working capital increase to $6.3 million as of September 30, 2025, compared to $4.8 million at the end of 2024. The company’s cash and cash equivalents stood at $10.5 million, down from $12.2 million at the end of the previous fiscal year. The company continues to face challenges related to supply chain disruptions and inflationary pressures, which could impact future operations and product availability.

Looking ahead, Stereotaxis plans to focus on advancing the adoption of its robotic magnetic navigation systems and proprietary devices in markets where regulatory clearance has been obtained. The company anticipates incurring additional losses as it invests in product development and commercialization efforts. While management believes that existing cash resources will suffice for operational needs, they acknowledge the potential need for additional funding in the future, depending on market conditions and operational demands.